Companies/KALA BIO, Inc.

Company profile

KALA BIO, Inc.

NASDAQ: KALA · Healthcare · Biotechnology

PublicHQ Arlington, MA · MiddlesexCIK 0001479419Reports USD

#1166 of 1,422 Healthcare companies by revenue

EA Score

30D

FH 27DQ 36GM 21SS 38

v0.1 · 65/100 weight · provisional

↑ balance-sheet leverage, disclosure history · ↓ 3-yr revenue growth, return on equity

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$27.0M

Employees

as of 2026-08-20

Market cap

$17.4M

as of 2026-08-20

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$0$02025

Net income-$27.0M-$27.0M2025

Operating income-$39.2M-$39.2M2025

Total assets$9.5M$9.5M2025

Liabilities$2.5M$2.5M2025

Equity$7.0M$7.0M2025

Revenue trend

FY2020 – FY2025 · USD

$833.0k

FY20

$2.2M

FY20

$6.4M

FY20

$11.2M

FY21

$3.9M

FY22

FY23

FY24

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is KALA BIO, Inc.’s revenue?

KALA BIO, Inc. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Barinthus Biotherapeutics plc39D Rein Therapeutics Inc.36D Ocumetics Technology Corp.——Tvardi Therapeutics, Inc.35D Palatin Technologies, Inc.40D Inhibitor Therapeutics, Inc.29D

Neighbors

Middlesex →

GE Vernova Inc.$38.1B63C Thermo Fisher Scientific Inc.$44.6B86A Analog Devices, Inc.$11.0B87A The TJX Companies, Inc.$60.4B85A Boston Scientific Corporation$20.1B88A Symbotic Inc.$2.2B49D

Key facts

CEOAvi Minkowitz

SectorHealthcare

IndustryBiotechnology

HeadquartersArlington, MA

ExchangeNASDAQ: KALA

Employees6

IPO date2017-07-20

Latest filings

8-K2026-08-28 10-Q2026-08-19 8-K2026-07-23 10-Q2026-05-15 8-K2026-05-07 10-K2026-04-15 8-K2026-03-04 8-K2026-02-20

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.